Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Eli Lilly and Company Limited
Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL
Telephone: +44 (0)1256 315 000
Fax: +44 (0)1256 775 858
WWW: http://www.lilly.co.uk
Medical Information e-mail: ukmedinfo@lilly.com
Medical Information Fax: +44 (0)1256 775 569

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 02/12/2011
PIL Zyprexa powder for solution for injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 02/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 03/11/2011 and displayed until 02/12/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 25/03/2011 and displayed until 03/11/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 03/02/2011 and displayed until 25/03/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Introduction of new pack/pack size
Updated on 16/11/2010 and displayed until 03/02/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to manufacturer contact details
Updated on 18/01/2010 and displayed until 16/11/2010
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to side-effects
Updated on 13/06/2008 and displayed until 18/01/2010
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 16/05/2008 and displayed until 13/06/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 04/02/2008 and displayed until 16/05/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 25/09/2007 and displayed until 04/02/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 01/11/2006 and displayed until 25/09/2007
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 10/07/2006 and displayed until 01/11/2006
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 28/04/2005 and displayed until 10/07/2006
Reasons for adding or updating:
  • Change to drug interactions
  • Change to date of revision
Updated on 18/02/2005 and displayed until 28/04/2005
Reasons for adding or updating:
  • Change to side-effects
Updated on 15/03/2004 and displayed until 18/02/2005
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 09/01/2004 and displayed until 15/03/2004
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
  olanzapine